budesonide + domperidone + omeprazole + salbutamol

This is a combination drug containing four active pharmaceutical ingredients: - Budesonide, a synthetic corticosteroid with potent glucocorticoid activity, primarily used to reduce inflammation in the airways. - Domperidone, a dopamine D2 receptor antagonist that acts as a prokinetic and antiemetic agent by enhancing gastrointestinal motility and blocking nausea/vomiting signals. - Omeprazole, a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells. - Salbutamol (also known as albuterol), a selective beta-2 adrenergic receptor agonist used as a bronchodilator to relieve bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease (COPD). The combination of these agents would theoretically provide anti-inflammatory effects for airway diseases (budesonide), relief of bronchospasm (salbutamol), protection against gastrointestinal symptoms or reflux potentially associated with corticosteroid use or respiratory disease comorbidities (omeprazole), and management of nausea/gastrointestinal motility issues that may arise from polypharmacy or underlying illness (domperidone). There is no evidence this specific four-drug combination is marketed under any unique brand name; it appears to be an unbranded multi-drug regimen.